The Technical AnalystExchange: HKSE Sector: Healthcare Industry: Biotechnology
Asymchem Laboratories Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.26% HKD63.10
America/New_York / 3 mai 2024 @ 01:47
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 30 318 mill |
| EPS: | 5.73 |
| P/E: | 11.01 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 480.48 mill |
| Avg Daily Volume: | 0.216 mill |
| RATING 2024-05-02 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.32x |
| Company: PE 11.01 | sector: PE 34.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.31x |
| Company: PE 11.01 | industry: PE 35.62 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD2.54 (-95.98%) HKD-60.56 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
HKD 59.81 - 66.39 ( +/- 5.22%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD63.10 (-5.26% ) |
| Volume | 0.0096 mill |
| Avg. Vol. | 0.216 mill |
| % of Avg. Vol | 4.44 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 6821.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
6821.HK
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.